<DOC>
	<DOCNO>NCT00703989</DOCNO>
	<brief_summary>Benfotiamine block three major pathway hyperglycemic damage prevents experimental diabetic retinopathy incipient nephropathy model . In cultured vascular cell , also reduce aldose reductase gene expression , activity , sorbitol level . It activate enzyme transketolase . α-lipoic acid , potent antioxidant , also report reduce diabetic microvascular macrovascular complication animal model . To determine whether benfotiamine combination α-lipoic acid would normalize marker ROS-induced pathway complication human , perform pilot study subject Type 1 diabetes use one daily dose benfotiamine combination α-lipoic acid .</brief_summary>
	<brief_title>Reactive Oxygen Species Pathogenesis Diabetic Complications</brief_title>
	<detailed_description>The glycemic status study patient assess measure baseline value HbA1c , fructosamine , fast plasma glucose . Mean HbA1c 8.7+ 0.7 % , mean fructosamine 421+29 mg/dl ( normal range 174-286 mg/dl ) , mean fast blood glucose 198+44 mg/dl . At day 0 , subject level marker two benfotiamine-sensitive pathway determine : intracellular advanced glycation endproduct ( AGE ) formation , reflect marker increase intracellular methylglyoxal adduct endothelial cell , angiopoietin 2 hexosamine pathway activity , measure determination N-acetylglucosamine-modified protein circulate monocyte . PKC activity circulate monocyte could measure amount blood require exceed approved Committee Clinical Investigations . Serum level 6-keto-PGF-1 , stable product produce nonenzymatic hydration antiatherogenic mediator prostacyclin also determine . Subjects take benfotiamine 300 mg twice day , ( Advanced Orthomolecular Research , Calgary , AB , CANADA ) slow-release α-lipoic acid ( 600 mg twice day ) ( MRI , San Francisco , CA ) 28 day . Blood obtain day 0 , day 15 , day 28 . Data analyze use 1-factor analysis variance compare mean group . The Tukey−Kramer multiple comparison procedure use determine pair mean different .</detailed_description>
	<mesh_term>Diabetes Complications</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<mesh_term>Benphothiamine</mesh_term>
	<criteria>Male Type 1 diabetes duration zero fifteen year current insulin therapy Female proliferative retinopathy microalbuminuria symptomatic diabetic neuropathy cardiovascular disease take medication smoke</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>hyperglycemia</keyword>
	<keyword>diabetic complication</keyword>
	<keyword>advanced glycation endproducts</keyword>
	<keyword>hexosamine pathway</keyword>
	<keyword>prostacyclin synthase</keyword>
	<keyword>reactive oxygen specie</keyword>
</DOC>